AACR 2024 Foreight | Three Oncology Studies From Kintor Pharma Selected
Release time：2024-04-02 14:00
2024 American Association of Cancer Research Annual Meeting (AACR 2024) will be held from April 5-10, 2024, in San Diego, United States. As the focal point of the cancer research community globally, countless latest scientific and medical studies in tumor field are first published here every year. In AACR 2024, one study of drug candidate GT0486 and two pre-clinical studies (including an anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from Kintor Pharma are selected. It demonstrates high research and development value of drug and pre-clinical studies, also signifies that the company’s innovative capabilities and potential for drug development have been internationally recognized. The abstracts are available on AACR’s official website.
Abstracts：
GT0486（mTORC1/2）
Title: GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitors
Session Category: Clinical Research
Session Title: Targeting Kinase and ERK Pathways
Session Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PM UTC
Location: Poster Section 46
Poster Board Number: 26
Nivo813（PD-1/ALK-1）
Title: High affinity and potent anti-tumor efficacy of Nivo813, an anti-PD-1/ALK-1 bispecific antibody, in pre-clinical studies for solid tumors
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Session Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM UTC
Location: Poster Section 6
Poster Board Number: 26
GT19870（GSPT1/Myc Molecular Glue）
Title: Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Molecular Glues
Session Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM UTC
Location: Poster Section 27
Poster Board Number: 4
Youzhi Tong, the founder, chairman, and CEO of Kintor, said, “Developing anti-cancer drugs is a challenging but profoundly meaningful task. We are pleased that our studies have demonstrated excellent R&D potential. Our GT0486, which can combo with BTK inhibitor, may overcome drug resistance issue; our Nivo813, which can bind potency to cell surface PD-1 and ALK-1 simultaneously, showing excellent anti-tumor effects both in vivo and in vitro; our GT19870, targeting the extremely difficult target c-Myc, has been showcased at international conferences multiple times. We will continue to delve into our research, hoping more patients can be benefit from R&D and technological innovation, and take the social responsibility as an innovative biotech company.”
recommend News
2024-07-01
2024-06-05
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn